Novartis unveils a new global R&D structure, creating centers in Cambridge, MA and Basel
Novartis is unveiling some big new changes to its R&D organization today, focusing heavily on new research operations based in Cambridge, MA as well as Basel while shuttering two units in China and Switzerland and relocating another from Singapore to the Bay Area.
Hot on the heels of its stunning decision to shut down its cell and gene therapy group while laying off 120, the company plans to tell employees at town hall meetings later today that it is establishing a new early-stage operation along with the creation of two new research centers. Here’s a quick look at the overall plan as outlined by Novartis in response to a query from Endpoints News:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.